China channel feed

Gen­script re­bounds on HKEX with staunch de­fense of Leg­end Biotech's CAR-T da­ta in­tegri­ty

7 years ago

Scathing short at­tack from an ob­scure source ac­cus­es Nan­jing Leg­end of ma­nip­u­lat­ing CAR-T da­ta — Gen­script shares nose­dive

7 years ago

With new $10.6B fund, Hill­house Cap­i­tal sets the stage for splashy Asia-fo­cused biotech deals

7 years ago
Financing
Startups

WuXi AppTec files for pub­lic list­ing in Hong Kong four months af­ter ex­plo­sive Shang­hai IPO

7 years ago
Financing
Outsourcing

An­oth­er sci­en­tist pleads guilty for his role in a scheme to sell GSK's trade se­crets in Chi­na

7 years ago
People
Pharma

Sanofi swaps top ex­ecs with Bay­er, trig­ger­ing a re­or­ga­ni­za­tion that puts Chi­na in the head­lights

7 years ago
People

Chi­nese phar­ma pow­er­house Han­soh joins fledg­ling biotechs in the Hong Kong IPO line

7 years ago
Financing

Chi-Med, Eli Lil­ly score a land­mark ap­proval in Chi­na for the first new can­cer drug de­vel­oped in Chi­na

7 years ago
Pharma

Glax­o­SmithK­line sci­en­tist cops a guilty plea in scheme to sell the phar­ma gi­ant's drug re­search in Chi­na

7 years ago

Qim­ing, Hill­house bet on Ja­co­bio's nascent pipeline of first-in-class drug hope­fuls in $55M round

7 years ago
Financing

As the maid­en biotech IPO on the HKEX fiz­zles, some in­vest­ment ex­perts see an up­side in tem­per­ing the hype

7 years ago
Financing
Pharma

Har­bour Bio­Med fol­lows can­cer drug deals with a hefty $85M Se­ries B backed by Sin­ga­pore's GIC

7 years ago
Financing

New­born bio­bet­ter, biosim­i­lar mak­er Mabpharm pitch­es the lat­est biotech IPO in Hong Kong

7 years ago
Financing

Bris­tol-My­ers will sell Op­di­vo in Chi­na at half of US cost, set­ting prece­dent for check­point wave — re­port

7 years ago
Pharma

Right on the heels of $150M raise, As­cen­t­age files the lat­est in a rush of HKEX biotech IPOs — but is the mar­ket too jit­tery?

7 years ago
Financing

Har­bour Bio­Med jumps in­to the crowd­ed PD-1/L1 race, look­ing to take a Chi­nese as­set glob­al as check­point pipeline bulges

7 years ago
R&D
Pharma

Roche picks up a speedy nod in Chi­na as reg­u­la­tors fol­low through on plans for a fast 48 new drug OKs

7 years ago
Pharma

For­mer head of Chi­na's FDA boot­ed in wake of sear­ing vac­cine scan­dal as lead­ers im­pose 'se­vere pun­ish­men­t'

7 years ago
R&D

Let's go to Chi­na: Join End­points in Shang­hai for the first US-Chi­na Bio­phar­ma In­no­va­tion & In­vest­ment Sum­mit — Oc­to­ber 22-23 #BI­IS18

7 years ago
Publisher's note

Eyes on Chi­na stocks: Lon­car loads new ETF with his picks for most promis­ing biotechs on HKEX and Nas­daq

7 years ago
Pharma

Gilead los­es key patent claims for So­val­di in Chi­na, open­ing door to ear­li­er gener­ic en­try

7 years ago

Chi­na reg­u­la­tors of­fer VIP treat­ment for 48 over­seas drugs they're ready to hus­tle up with ac­cel­er­at­ed re­views

7 years ago
Pharma

Tout­ing its man­u­fac­tur­ing strengths, Tot Bio­pharm rais­es $102M mega-round to ramp up can­cer R&D

7 years ago
Financing

BeiGene takes a hit af­ter his­toric $903M Hong Kong IPO with neg­a­tive biotech sen­ti­ment

7 years ago
Financing
First page Previous page 22232425262728 Next page Last page
A service from the Financial Times